A year after Roche Alzheimer’s failure, scientists reflect on what could have been: Fierce Biotech

Fierce Biotech quoted Lon Schneider, M.D., professor of psychiatry & the behavioral sciences, and Della Martin Chair in Psychiatry and Neuroscience, commenting on Roche’s Alzheimer’s failure with the drug gantenerumab. “It is surprising that two phase 3 trials of gantenerumab, the results of which are reported in this issue of the Journal, did not show significant benefits, given that gantenerumab is similar to aducanumab and lecanemab.”

• A year after Roche’s Alzheimer’s failure, scientists reflect on what could have been